University of Kuopio
VP22 does not significantly enhance enzyme prodrug cancer gene therapy
Published in Genetics and Environmental Business Week, December 8th, 2005
"VP22 is a HSV type-1 tegument protein that has been suggested to spread from cell to cell, alone or as a part of fusion proteins. Creating controversy, some reports indicate that VP22 cannot facilitate significant intercellular spreading."
"To study the capacity of VP22 to cause spreading and enhance thymidine kinase/ganciclovir cancer gene therapy, we constructed a novel triple fusion protein containing VP22, HSV thymidine kinase and green fluorescent protein...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics and Environmental Business Week
More Articles from Genetics and Environmental Business Week
- Cepheid
Genetic assessment company reports third-quarter 2005 results - Human Genome Sciences, Inc.
Genomics firm calls for all remaining outstanding subordinated notes due 2007 - Targeted Genetics Corporation
Biotechnology company reports third quarter net loss of $5.7 million - Transgenomic Inc.
Provider of research tools closes announced private placement of common stock - ZymoGenetics, Inc.
Company developing therapeutic proteins reports net loss of $20.4 million - Aarhus University Hospital
Mutations in arginine vasopressin gene indicate genotype-phenotype correlation in FNDI - More from this issue of Genetics and Environmental Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
